Researchers are excited about the medication , a novel dual agonist showing significant data in initial trials for size reduction . It acts by modulating several pathways : GLP-1 and GIP, which , when engaged , assist control hunger and enhance energy expenditure . Initial reports demonstrate considerable weight loss and potential benefits for peop